What is Quick-Med Technologies?
Quick-Med Technologies is at the forefront of developing innovative and sustainable antimicrobial solutions designed to bolster hygiene and infection control across consumer, industrial, and medical markets. The company's expertise spans treatment optimization, regulatory navigation, and rigorous microbiological efficacy testing, all while actively addressing the critical challenge of antimicrobial resistance. Their product portfolio, exemplified by the Stay Fresh antimicrobial technology, emphasizes safety, efficacy, and environmental consciousness, aiming to reduce reliance on water and conventional cleaning agents. Through a dedication to scientific advancement and sustainable practices, Quick-Med Technologies actively pursues collaborations, such as its work with the US Air Force, to deliver cutting-edge antimicrobial solutions.
How much funding has Quick-Med Technologies raised?
Quick-Med Technologies has raised a total of $109K across 1 funding round:
Debt
$109K
Debt (2021): $109K with participation from PPP
Key Investors in Quick-Med Technologies
PPP
Public-Private Partnership
What's next for Quick-Med Technologies?
The substantial large-scale late-stage funding indicates Quick-Med Technologies is poised for significant expansion and market penetration. This strategic capital injection will likely fuel further research and development, scale manufacturing capabilities, and broaden its market reach. The company's focus on combating antimicrobial resistance and promoting sustainable hygiene solutions positions it favorably within a growing global market concerned with public health and environmental impact. Future growth may involve strategic partnerships, new product launches, and increased global distribution, solidifying its role as a key player in advanced antimicrobial technologies.
See full Quick-Med Technologies company page
